Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Current Assets (2016 - 2025)

Historic Current Assets for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Q3 2025 value amounting to $529.8 million.

  • Syndax Pharmaceuticals' Current Assets rose 2772.87% to $529.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $529.8 million, marking a year-over-year increase of 2772.87%. This contributed to the annual value of $603.1 million for FY2024, which is 381.85% up from last year.
  • Syndax Pharmaceuticals' Current Assets amounted to $529.8 million in Q3 2025, which was up 2772.87% from $531.7 million recorded in Q2 2025.
  • Syndax Pharmaceuticals' Current Assets' 5-year high stood at $603.1 million during Q4 2024, with a 5-year trough of $238.3 million in Q3 2021.
  • For the 5-year period, Syndax Pharmaceuticals' Current Assets averaged around $433.1 million, with its median value being $441.5 million (2023).
  • As far as peak fluctuations go, Syndax Pharmaceuticals' Current Assets surged by 16768.8% in 2021, and later soared by 280.58% in 2024.
  • Quarter analysis of 5 years shows Syndax Pharmaceuticals' Current Assets stood at $448.4 million in 2021, then grew by 9.23% to $489.8 million in 2022, then rose by 18.6% to $580.9 million in 2023, then increased by 3.82% to $603.1 million in 2024, then dropped by 12.14% to $529.8 million in 2025.
  • Its last three reported values are $529.8 million in Q3 2025, $531.7 million for Q2 2025, and $548.8 million during Q1 2025.